Quoin Pharmaceuticals to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 10th
Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) announced that it will report its third quarter 2022 financial results on November 10, 2022, before the market opens. Management will conduct a webcast and conference call at 8:30 a.m. ET on the same day to discuss the results and corporate updates. The dial-in numbers for the call are 1-877-270-2148 (domestic) and 1-412-902-6510 (international). Quoin focuses on developing therapeutics for rare and orphan diseases, with a pipeline targeting conditions like Netherton Syndrome and Epidermolysis Bullosa.
- None.
- None.
ASHBURN, Va., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its third quarter 2022 financial results will be reported on Thursday, November 10, 2022 before the open of the financial markets. Management will also host a webcast and conference call on November 10, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update.
The live call can be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international).
The live and archived webcast of the call will be available on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates.
For further information, contact:
Investor Relations
PCG Advisory
Stephanie Prince
sprince@pcgadvisory.com
(646) 863-6341
FAQ
When will Quoin Pharmaceuticals report its third quarter 2022 financial results?
What time is the conference call for Quoin Pharmaceuticals' financial results?
How can I access the webcast for Quoin Pharmaceuticals' financial results?
What is the focus of Quoin Pharmaceuticals' development pipeline?
